Long‐Term Clinical‐Pathologic Results of Enzyme Replacement Therapy in Prehypertrophic Fabry Disease Cardiomyopathy
Background The limited ability of enzyme replacement therapy (ERT) in removing globotriaosylceramide from cardiomyocytes is recognized for advanced Fabry disease cardiomyopathy (FDCM). Prehypertrophic FDCM is believed to be cured or stabilized by ERT. However, no pathologic confirmation is available...
Збережено в:
| Автори: | , , , , , , , , , , , |
|---|---|
| Формат: | Artigo |
| Мова: | Inglês |
| Опубліковано: |
Wiley
2024-04-01
|
| Серія: | Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease |
| Предмети: | |
| Онлайн доступ: | https://www.ahajournals.org/doi/10.1161/JAHA.123.032734 |
| Теги: |
Немає тегів, Будьте першим, хто поставить тег для цього запису!
|